Physiomics lands contract with UK-based biotech

Physiomics has been awarded a contract worth £48,000 by a new UK-based biotech client.

The project, which is due to complete in this calendar year, will focus on the translation of pre-clinical to clinical results in support of a first in man study of a novel cancer drug.

Physiomics said this is an area of increasing focus and one where it believes its technology and experience can really add value whether working for small biotechnology or global pharmaceutical companies.

Chief executive officer Jim Millen said: "We are pleased that we are keeping up the momentum of new business contracts following on from the previously announced signing of deals with three big pharmaceutical companies in the last six months."

AIM-listed Phyisomics provides technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry.

At 1250 BST, the shares were down 0.7% to 6.66p.